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1. Introduction 
The amyloidoses are a group of protein-misfolding disorders characterized by the 
accumulation of amyloid fibrils formed from a variety of proteins. Currently, twenty- eight 
different kinds of human and animal proteins, in intact or fragmented forms, have been 
found to be associated with pathological disorders such as Alzheimer’s disease, type II 
diabetes, prion diseases, dialysis-related amyloidosis, and various familial, senile and 
sporadic amyloidosis (Sipe et al., 2010; Benson et al 2008). Amyloidoses have been divided 
into two major classes: 1) systemic and 2) localized amyloidoses. In systemic amyloidoses, 
precursor proteins circulating in the blood associate to form amyloid fibrils that are then 
deposited throughout the body.  For example, immunoglobulin light chains form deposits in 
patients with myeloma in AL amyloidosis. In reactive AA amyloidosis, serum amyloid A 
(SAA) protein forms deposits in patients with chronic inflammation, and transthyretin 
(TTR) forms deposits in patients with familial amyloid polyneuropathy (FAP) and senile 
systemic amyloidosis (SSA). Patients on long-term hemodialysis develop dialysis-related 
amyloidosis (DRA) due to the deposition of amyloid fibrils (Aß2M) of ß2-microglobulin 
(ß2m). In contrast to systemic amyloidosis, precursor proteins produced in local organs 
deposit in one particular area of the body in various localized amyloidoses.  
In mice, apolipoprotein A-II (apoA-II) in serum high density lipoproteins (HDL) forms 
amyloid fibrils (AApoAII) in age-associated systemic amyloidosis (senile AApoAII 
amyloidosis). AA amyloidosis, known as reactive or secondary amyloidosis associated with 
inflammation, is generally recognized as the predominant form of systemic amyloidosis that 
occurs in humans, mice, domestic animals and many species in the animal kingdom. These 
amyloidoses are characterized by the systemic deposition of extracellular fibrils composed 
of apoA-II in AApoAII amyloidosis or SAA (serum AA) in AA amyloidosis, primarily in the 
spleen, liver, heart, kidney, vessels walls, and to a lesser extent in other organs. In most 
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species, AApoAII and AA amyloidosis occurs sporadically and is associated with aging 
(AApoAII amyloidosis) and chronic inflammation (AA amyloidosis).  However, intriguing 
recent data suggest that both AApoAII and AA amyloidoses could be transmitted by a 
prion-like infectious process through a seeding-nucleation mechanism (Qian et al., 2010; B. 
Zhang et al., 2008). In these amyloidoses, AApoAII and AA amyloid fibrils, abnormal forms 
of the host serum proteins (apoA-II and SAA), induce conformational changes in apoA-II 
and SAA to form AApoAII and AA fibrils, and this causes detectable phenotypes or 
diseases in affected individuals. Recently, Aß amyloid fibrils in Alzheimer’s disease and 
intracellular amyloid fibril-like aggregated proteins were postulated to work as seeds for 
propagation of mis-folded and pathologic protein structures in various neurodegenerative 
disorders, including Huntington’s disease, Parkinson’s disease and tauopathies (Aguzzi et 
al., 2009; Brundin et al., 2010).  
The prion-like transmission of amyloid fibrils or fibril-like materials, which could play an 
important role in the propagation of pathological events in systemic amyloidosis, will be 
discussed here.     
2. Transmission of mouse senile AApoAII amyloidosis 
Several senescence-prone inbred strains of mice (SAMP strains) have been developed with 
accelerated senescence, a shorter life span and various age-associated disorders and 
pathologic changes. These SAMP strains include SAMP1, SAMP6, SAMP8 and SAMP10. An 
accelerated senescence-resistant strain (SAMR1) has also been generated to serve as a 
control for the SAMP strains (Takeda et al., 1981; Higuchi et al., 1999). Severe senile 
amyloidosis is a characteristic age-associated disorder in the SAMP1 and SAMP10 strains, 
making them a valuable model to investigate amyloidosis pathogenesis and to assist in the 
development of effective therapeutic modalities. We identified apoA-II, a normal constituent 
of serum HDL, as the amyloid protein responsible for mouse senile amyloidosis in the 
SAMP1 strain, and the amyloid fibril was named AApoAII (Higuchi et al., 1983; Yonezu et 
al 1986; Higuchi et al. 1986). Recently we found that there was prion-like transmission in 
mouse AApoAII amyloidosis (Higuchi et al., 1998; Xing et al., 2001). Here, a brief history 
and the pathobiology of mouse AApoAII amyloidosis in SAMP1 and its related strains is 
described, followed by a discussion of AApoAII amyloidosis transmission. 
2.1 Pathology of mouse AApoAII amyloidosis 
Amyloid fibril deposition in aged SAMP1 mice is systemic and all organs except brain 
parenchyma are involved (Takeshita et al., 1982). The earliest AApoAII deposits are seen in 
the primary and secondary papillae of the tongue, the lamina propria and submucosa of the 
small intestine, the alveolar septa of the lungs and the squamous-glandular junction of the 
stomach. With advancing age, AApoAII deposits extend into the collecting tubules in the 
papillae of the kidneys, the perimedullary zone of the adrenal cortex, heart and skeletal 
muscle interstitium, thyroid gland interstitium, the papillary layer of the dermis, the testis 
interstitium, the corpora lutea, the atretic follicle and the ovarian interstitium, around the 
portal veins and in the spaces of Disse in the periportal sinusoid of the liver, the marginal 
zone around the lymphoid follicles of the spleen, and blood vessels throughout the body. In 
the final stage, the liver and spleen are enlarged and the kidneys are contracted with severe 
amyloid deposition (Higuchi et al. 1983) (Fig. 1). 
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Fig. 1. Mouse systemic senile amyloidosis in SAMP1 mice. AApoAII amyloid fibrils were 
deposited in the whole body except for the brain parenchyma.  Upper-left: heavy amyloid 
deposition in a liver section strained with Congo red was detected as green birefringence 
under the polarizing microscope (X100). Upper-right and Lower-left: AApoAII amyloid 
depositions were determined immunohistochemically in the heart and tongue, respectively 
(X400). Lower-right; Electron microscopic observation of AApoAII amyloid fibrils isolated 
from the liver (X50,000). 
Although senile AApoAII amyloidosis is common in most mouse strains, severe senile 
amyloidosis has been reported in only a few strains, i.e. SAMP1, SAMP10, SJL/J, LLC, and 
PS strains. The complete nucleotide sequence of the apoA-II (gene is Apoa2) cDNA was 
determined in 41 inbred strains of mice (Kunisada et al., 1986; Kitagawa et al., 2003). Among 
these strains, six alleles containing amino acid substitutions (Apoa2a, Apoa2b, Apoa2c, Apoa2d, 
Apoa2e and Apoa2f) were identified. Severe amyloid deposition was observed in the strains 
with the Apoa2c allele (Higuchi et al., 1991). Several genetic analyses indicated that the 
presence of the Apoa2c allele markedly accelerates age-associated deposition of AApoAII 
and reduces the lifespan (Naiki et al., 1993; Higuchi et al., 1995; 1996). These results show 
that type C apoA-II protein in mice is highly amyloidogenic, while SAMR1 and strains with 
type B apoA-II protein are resistant to the development of amyloidosis. The mice expressing 
type A apoA-II protein, such as C57BL/6, are moderately amyloidogenic. In vitro amyloid 
fibril formation (fibril extension) has been reported with the type C apoA-II protein, but not 
with the type B apoA-II (Naiki et al., 1992; Fu et al., 2001). Recently we demonstrated that 
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the combination of N- and C-terminal sequences of mouse apoA-II and a conformational 
change in their secondary structure are essential for polymerization into AApoAII amyloid 
fibrils (Sawashita et al., 2009). However, the mechanism behind the high amyloidogenicity 
of type C apoA-II protein in vivo is not yet known. 
Congenic R1.P1-Apoa2c mice have the amyloidogenic Apoa2c SAMP1 gene on the genetic 
background of SAMR1 (Higuchi et al., 1993). Comparable to the donor SAMP1 strain, severe 
amyloid deposition is present in the R1.P1-Apoa2c strain (Higuchi et al., 1995), and the R1.P1-
Apoa2c mice are more convenient for use in amyloidosis experiments. A transgenic mouse 
strain that over-expresses Apoa2c mRNA has been established on the genetic background of 
R1.P1-Apoa2c. This strain shows higher concentration of apoA-II and greater susceptibility to 
amyloidosis than the control R1.P1-Apoa2c strain and should prove valuable in future 
studies of amyloidosis (Ge et al., 2007). 
2.2 Transmission of mouse AApoAII amyloidosis 
Nucleation-dependent polymerization is a postulated model consistent with the kinetics of 
in vitro amyloid protein fibrillization in amyloidoses such as prion diseases, Alzheimer 
disease and mouse AApoAII amyloidosis (Jarrett et al., 1993; Harper et al., 1997; Naki et al., 
1991). This model is comprised of two phases: 1) nucleation and 2) extension. 1) Nucleus 
formation requires a series of thermodynamically unfavorable monomer association steps. 
Thus, the nucleation phase is the rate-limiting step in the development of amyloidosis. 2) 
Once the nucleus has formed, further addition of monomers becomes thermodynamically 
favorable, resulting in rapid extension of amyloid fibrils. The dramatically hastened in vitro 
fibril formation fueled by the addition of amyloid fibrils (nucleus) to a solution of amyloid 
protein monomers is an example of nucleation-dependent polymerization.  
Prion diseases are associated with the accumulation of a pathologic conformational isomer 
(PrPSc) by a host-derived prion protein (PrPc). Prion transmission or propagation involves 
the conversion of cellular PrPc into PrPSc via an increase in its ß-sheet secondary structure 
content. According to the protein-only hypothesis, introduction of the abnormal conformer 
PrPSc into an organism would accelerate the conversion of PrPc into its pathological 
conformation (Prusiner et al., 1998; 2006). Thus, the nucleation-dependent polymerization 
model provides a feasible mechanism for the in vivo conformational conversion of PrPc to 
PrPSc via transmission of prions (Weissmann et al, 1999). 
As predicted by the nucleation-dependent polymerization model, in vitro fibril formation 
experiments in which apoA-II monomers are converted to AApoAII fibrils indicate that 
the addition of AApoAII amyloid fibrils can facilitate the formation of amyloid fibrils 
from apoA-II monomers (seeding reaction)(Fig. 2A). Amyloid deposition was notably 
accelerated after a very small quantity of AApoAII fibrils was administered to R1.P1-
Apoa2c mice by peripheral injection (intravenous, intraperitoneal or intragastric) or in the 
diet (Fig. 2B) (Higuchi et al., 1998; Xing et al., 2001). Thus, fibril formation is greatly 
accelerated in mice through seeding with pre-formed fibrils in vivo in mice (transmission 
of amyloidosis). The acceleration of amyloidosis fibrils (transmissibility) disappeared 
completely after treatment with protein denaturing reagents including 6 M guanidine 
hydrochloride, strong alkaline solution or formic acid. Acceleration was slowed by 6 M 
urea or by autoclaving, and it was not changed by formalin, DNAse or RNAse treatments. 
This finding revealed that transmissibility of AApoAII depends on fibril conformation (H. 
Zhang et al., 2006). 
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Fig. 2. Transmission of mouse AApoAII amyloidosis in vitro and in vivo. A: Addition of 
AApoAII amyloid fibrils to a solution of apoA-II monomers accelerates fibril formation in 
test tubes. B: Injection of AApoAII amyloid fibrils into R1.P1- Apoa2c mice accelerates 
amyloid deposition. C: Amyloid deposition is accelerated in offspring born to and nursed by 
mothers with amyloidosis. D: Young R1.P1- Apoa2c mice that were kept in the same cage 
with mice having amyloidosis for 3 months developed amyloidosis.  The intensity of 
amyloid deposition in mice was determined semi-quantitatively using the amyloid index 
(AI) as a parameter. The AI parameter represents the average degree of deposition, graded 0 
to 4, in Congo red - stained sections from the seven organs examined (liver, heart, spleen, 
tongue, stomach, intestine and skin). 
Amyloidosis in the offspring of R1.P1- Apoa2c mice was examined to further characterize 
this transmissibility. Acceleration of amyloidosis was observed in offspring born to, and 
nursed by, mothers with amyloidosis that was induced by injection of amyloid fibrils 3 
months before pregnancy (Fig. 2C) compared with the offspring of control mothers that did 
not receive injections of amyloid fibrils (Korenaga et al., 2006). Acceleration of amyloidosis 
was also observed in offspring born to mothers that were not injected, but that were nursed 
by mothers injected with amyloid fibrils. However, this phenomenon was not observed in 
offspring born to amyloidosis mothers and nursed by control mothers. Injection of milk 
obtained from amyloid fibril-injected mothers induced AApoAII amyloidosis in young 
mice, and amyloid fibrils were detected in the milk of amyloid fibril-injected mothers by 
electron microscopy. Young mice were reared for 3 months in cages with old R1.P1- Apoa2c 
mice that had severe amyloid-depositions. All of the young mice developed amyloid 
deposits (Fig. 1D)(Xing et al., 2001). Amyloid fibrils were detected in feces of mice with 
amyloidosis. Injection of amyloid fibrils found in feces induced amyloidosis in mice, raising 
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the possibility that the oral transmission of amyloid fibrils through feces leads to 
acceleration of amyloidosis in AApoAII amyloidosis.  AApoAII amyloid fibril deposits were 
found in the skeletal muscles of amyloid-affected mice, primarily in the blood vessels and in 
the interstitial tissues (endomysium) surrounding muscle fibers (Qian et al., 2010). Amyloid 
fibril fractions isolated from the muscles could also induce amyloidosis in young mice. 
2.3 Cross-seeding of amyloidosis 
The induction of AApoAII amyloidosis was studied in vivo using various kinds of amyloid 
fibrils that were isolated from human and mouse tissues or were formed in vitro from 
synthetic peptides and recombinant proteins. The fibrils were injected intravenously into 
young R1.P1-Apoa2c mice. At 3 and 6 months after injection, the most severe amyloid 
depositions were detected in mice injected with mouse AApoAII(C) amyloid fibrils 
composed of amyloidogenic C type apoA-II, (Fu et al 2004, Yan et al., 2007). Mild amyloid 
depositions were also detected in tissues of mice that had been injected with other types of 
fibrils, including synthetic peptides and recombinant proteins. However, no amyloid 
depositions were found in mice injected with non-amyloid fibril proteins such as serum 
albumin, transthyretin and mouse apoA-II. This cross-seeding model postulates that there is 
a direct interaction between newly forming and preexisting heterologous amyloid fibrils in 
vivo. Thus, induction by various amyloid fibrils supports the prospect of amyloidosis 
acceleration in animals and humans by heterogeneous amyloid and amyloid-like fibrils in 
foods or the environment.   
AApoAII(C) fibrils were injected intravenously into 2-month-old SAMR1 mice, which 
carry the less amyloidogenic apoA-II allele (Apoa2b) and develop few, if any, spontaneous 
amyloid deposits. Ten months after the amyloid injection, deposits were detected on the 
tongue, and the intensity of deposition increased thereafter, whereas no amyloid was 
detected in SAMR1 mice injected with distilled water, even after 20 months (Xing et al., 
2002). The deposited amyloid fibrils were composed of endogenous type B apoA-II 
protein, with a different amyloid fibril conformation of the proto-fibril-like figure. 
Subsequent injection of these AApoAII(B) fibrils induced earlier and more severe 
amyloidosis in SAMR1 mice than did the first injection of AApoAII(C) fibrils.  Thus, 
adaptation of amyloid fibril structure might happen during deposition in SAMR1 mice.  
AApoAII(A) fibrils composed of mild amyloidogenic apoA-II allele (Apoa2a) were isolated 
from the intestine and liver of C57BL/6 mice. Atomic force microscopy and transmission 
electron microscopy revealed that the majority of isolated AApoAII(A) fibrils have fine, 
proto-fibril-like shapes. The AApoAII(A) fibril has a much weaker affinity for thioflavin T 
than does the AApoAII(C) fibril. The injection of AApoAII(A) fibrils induced amyloid 
deposition in C57BL/6 mice (Apoa2a) as well as in R1.P1-Apoa2c mice (Apoa2c). However, 
the AApoAII(A) fibrils induced more severe amyloidosis in Apoa2a strains than in the 
Apoa2c strain (Korenaga et al., 2003).  
These findings indicate that AApoAII(A) fibrils isolated from mice having the mild-
amyloidogenic type A apoA-II, and AApoAII(B) fibrils isolated from mice having the less-
amyloidogenic type B apoA-II, have distinct morphological, pathological and structural 
characteristics that differ from those of the AApoAII(C) fibrils of amyloidogenic type C 
apoA-II. Consequently, cross-seeding with the amyloid fibrils induced amyloid deposition 
in mice that had amyloid protein monomers with different primary structures.  
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3. Transmission of mouse reactive AA amyloidosis 
AA amyloidosis, also known as reactive or secondary amyloidosis, is generally recognized 
as the predominant form of systemic amyloidosis that occurs in the human and animal 
kingdoms (Sipe & Cohen, 2000). The disease is characterized by systemic deposition, 
primarily in the spleen, liver and, to a lesser extent, in other organs, of extracellular fibrils 
composed of amyloid A protein. In most species, AA amyloidosis typically occurs 
secondary to chronic inflammation, infection or neoplasia.   SAA protein is an acute phase 
apolipoprotein reactant primarily produced by hepatocytes under the control of interleukin-
1, interleukin-6, and tumor necrosis factor-α (Betts et al., 1993; Hagihara et al., 2005). The 
plasma concentration of SAA is normally very low, but it can increase to > 1,000 mg/liter 
following an inflammatory stimulus. This protein can be proteolytically processed to 
produce an N-terminal cleavage product of approximately 44 to 100 residues that is 
deposited as amyloid in vital organs including the spleen, liver, and kidneys (Kisilevsky et 
al., 1994). AA amyloidosis occurs in patients with rheumatoid arthritis and other chronic 
inflammatory diseases. AA can also be induced experimentally in mice by injecting them 
with silver nitrate, casein, or lipopolysaccharide (LPS), which greatly increases the 
concentration of circulating SAA (Hoffman & Benditt, 1982). Intriguing recent data have led 
to the suggestion that AA amyloidosis might also be transmitted by a prion-like infectious 
process that involves a seeding-nucleation mechanism, a model that is widely accepted 
(Lundmark, et al., 2002, 2005; Cui et al., 2002). The lag phase of AA amyloidogenesis can be 
dramatically shortened by co-injection of “amyloid enhancing factor (AEF)” with an acute 
inflammatory stimulus. There is evidence that AEF is actually AA fibrils, and that AA 
amyloidosis might be transmitted by a prion-like mechanism.   
3.1 Transmission of AA amyloidosis in cheetah and cattle 
The cheetah species (Acinonyx jubatus) is in danger of extinction and is included on The 
World Conservation Union list of vulnerable species. Although efforts have been made in 
wildlife sanctuary parks and zoos worldwide to prevent extinction, a steady increase in the 
size of the cheetah population is hampered by the high prevalence of systemic AA 
amyloidosis, which is regarded as an increasingly important cause of morbidity and 
mortality in captive cheetahs (Papendick et al 1997). Inflammatory diseases, especially 
chronic lymphoplasmacytic gastritis, were found in 100% of cheetahs with AA amyloidosis, 
and environmental epidemiological studies indicate that breeding conditions have a 
prominent effect on the incidence of AA amyloidosis. A high rearing density is always 
associated with early age of onset and with a high incidence and severity of AA 
amyloidosis.  We hypothesize that the propagation of AA amyloidosis among captive 
cheetah populations may depend on a horizontal transmission pathway (B. Zhang et al., 
2008). 
Captive cheetahs with severe AA amyloidosis were studied. AA amyloid fibrils were 
isolated from several tissues and the biochemical and pathological future outcomes of 
the animals were recorded. In particular, we hypothesized that amyloid fibrils in feces, 
urine and saliva would be important for the conveyance of amyloid fibrils from the body 
into the environment and hence for horizontal transmission. We found that cheetah feces 
contained AA amyloid fibrils that were different from those in the liver, having a smaller 
molecular weight and a shorter and finer shape. However, we could not find amyloid 
fibrils in the urine, and unfortunately we could not collect saliva from cheetahs. We 
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compared the transmissibility of fecal and liver AA amyloid fibrils using the mouse 
experimental AA amyloidosis system. Fecal amyloid fibrils had significantly greater 
transmissibility (Fig. 3A). The infectious activity of fecal AA amyloid fibrils was reduced 
or abolished by the protein denaturants 6 M guanidine HCl and formic acid or by AA 
immunodepletion. With regard to the liver fraction, formic acid treatment caused a 
nearly complete loss of amyloid-inducing activity, whereas the guanidine-HCl-treated 
fraction retained high amyloid-inducing activity (Fig. 3B). Thus, we unexpectedly found 
that the amyloid fibril fraction from feces had smaller amyloid fibrils and higher 
sensitivity to denaturation treatment than the liver amyloid fibril fraction. In yeast 
prions, it also has been indicated that [PSI+] with stronger infectivity typically have less 
stable fibrils in vivo than strains with weaker infectivity (Krishnan & Lindquist, 2005), 
and the prion strain with relatively smaller prion particles is always associated with 
greater fragility and increased sensitivity to denaturants (Tanaka et al., 2006). Thus, we 
propose that feces are a potential transmission vehicle that may accelerate AA 
amyloidosis in captive cheetah populations. These results provide a pathogenic 
mechanism for AA amyloidosis and suggest possible measures for rescuing cheetahs 
from extinction. 
 
 
Fig. 3. Transmissibility and fragility of fecal AA amyloid fibrils. A: Quantification of 
transmissibility of AA amyloid fibrils from feces and liver. The degree of AA deposition 
in AA-induced mice was determined by isolation of AA amyloid fibril fractions from the 
spleens of mice in each group (filled circle is fecal; open circle is liver) followed by 
Western blot analysis and quantification using an image analyzer. The means and SE were 
determined by the relative ratios of AA amyloid protein levels versus the group receiving 
10 µg of amyloid fibrils fraction from the feces (*, P < 0.05). B: Fecal and liver AA amyloid 
fibril fractions were untreated (N), or treated with guanidine-hydrochloride (G) or formic 
acid (F) and injected into mice to induce AA amyloidosis. Equal quantities of amyloid 
fractions (100 µg) were used in each experiment. The degree of amyloidosis was 
determined by the amyloid deposition observed in Congo red-stained sections of the 
spleen. 
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4. Analysis of transmission in mouse models of another systemic 
amyloidosis 
Patients on long-term hemodialysis can develop dialysis-related amyloidosis (DRA) due 
to deposition of ß2-microglobulin (ß2m) into amyloid fibrils (Aß2M) (Gejyo et al., 1985). 
Despite intensive biochemical studies, the pathogenesis of amyloid deposition in DRA 
patients remains poorly understood. Intact wild type ß2m is unable to form amyloid 
fibrils under physiological conditions in test tubes. However, the addition of Aß2M 
amyloid fibrils induces fibril formation following a nucleation dependent polymerisation 
model (Yamaguchi et al., 2001; Xue et al., 2008). To elucidate the mechanisms that 
underlie Aß2M fibril formation in DRA, transgenic mice were generated that overexpress 
human ß2m protein on a mouse ß2m gene knockout background (hB2MTg+/+mB2m -/-), 
and the possibility of transmission was examined using these model mice (P. Zhang et 
al., 2009). 
Families with a variant transthyretins (TTR V30M)-associated familial amyloidotic 
polyneuropathy (FAP) exhibit genetic anticipation, with TTR V30M-amyloid depositing 
noted at an earlier age in successive generations (Yamamoto et al., 1998). The molecular 
basis of anticipation in FAP remains to be determined. The possibility that ATTR 
amyloid fibrils might be excreted in the milk of the FAP patients was suggested (Tokuda 
et al., 2007).  We asked if administration of TTR-amyloid fibrils (ATTR) extracted from 
the heart of an FAP TTR V30M patient would accelerate ATTR deposition in transgenic 
mice expressing the human mutant TTR gene responsible for FAP TTR V30M (Wei et al., 
2004).  
4.1 Analysis of the transmission of Aß2M amyloidosis in human ß2m transgenic mice 
Transgenic mice that overexpress human ß2m protein were generated on a mouse B2m 
gene knockout background (hB2MTg+/+, mB2m-/-). First, the pCAGGS-hB2M vector was 
created, and a human ß2m gene (hB2M) cDNA fragment was isolated by reverse 
transcription-PCR (RT-PCR) of messenger RNA extracted from human liver and cloned 
into pCAGGS. The hB2M cDNA was expressed under the control of the cytomegalovirus 
immediate early gene enhancer (CMV-IE)/chicken ß-actin promoter and rabbit ß-globin 
poly(A) signal (Fig. 4). The hB2M transgene copy number was determined by real-time 
PCR and calculated as 10 for homozygous hB2MTg+/+. To exclude possible effects of 
endogenous mouse ß2m, transgenic mice were crossed with mouse ß2m (mB2m) 
knockout mice. The hB2MTg+/+, mB2m-/- mice express a high level of human ß2m protein 
in many tissues and also have a high plasma ß2m concentration (192.8 mg/L). This 
concentration is >100 times higher than that observed in healthy humans and >4 times 
higher than that detected in patients on dialysis. These mice were checked for 
spontaneous amyloidosis, but amyloid deposition of ß2m protein was not observed in 
aged (~2 years) mice. Next we attempted to accelerate amyloidosis by injecting human 
Aß2M amyloid fibrils isolated from the amyloid-laden ligaments of the patient, and 
artificial amyloid fibrils were produced from recombinant human ß2m protein. Amyloid 
deposition of ß2m protein was not observed in animals injected with amyloid fibrils. 
However, mouse senile AApoAII amyloidosis was detected, particularly in the joints of 
mice that were injected with amyloid fibrils. 
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Fig. 4. Establishment of hB2M transgenic mice. The pCAGGS-hB2M targeting vector 
containing the human ß2m cDNA inserted between the CMV-IE enhancer/chicken ß-actin 
promoter and the rabbit ß-globin poly(A) site. 
This study demonstrates that this mouse model could be valuable in studying the 
components and conditions that promote DRA, and the results indicate that neither high 
plasma concentrations of hß2m nor seeding with pre-existing amyloid fibrils may be 
sufficient to induce Aß2M.  We attempted to enhance amyloidosis by inducing arthritis 
through injection of the following substances: a monoclonal antibody against type II 
collagens, LPS (which induces inflammatory reactions), type I collagen and heparin 
solution, all of which are known to induce amyloid fibril formation in the test tube (Relini et 
al., 2006; Bellotti & Chiti, 2008).   However, we have not been able to induce Aß2M amyloid 
deposition in mice. 
4.2 Analysis of the transmission of TTR amyloidosis in human variant TTR transgenic 
mice 
Transgenic mice producing human variant TTR due to a mutant TTR (V30M) gene with its 
endogenous 6.0 kb upstream region were generated by Maeda et al (Kohno et al., 1997). The 
variant TTR transgene copy number was determined to be ~ 60 for homozygous hTTR-
V30MTg+/+. To exclude possible effects of endogenous mouse Ttr, transgenic mice were 
crossed with Ttr knockout mice.  The Ttr -/-, hTTR-V30MTg+/? mice expressing a high level of 
human variant TTR protein, which was produced mainly in the liver, were used (Fig. 5). 
 
 
Fig. 5. Establishment of Ttr-/-, hTTR-V30MTg+/? mice. Variant human Ttr transgenic mice 
were crossed with mouse Ttr knockout mice. 
We asked if administration of TTR-amyloid fibrils (ATTR) extracted from the heart of an 
FAP TTR V30M patient would accelerate ATTR deposition in these transgenic mice.  
Although the administration of amyloid fibrils did accelerate deposition of AApoAII fibrils 
www.intechopen.com
Mouse Models to Study Systemic Amyloidoses:  
Is Prion-Like Transmission a Common Pathogenic Mechanism? 
 
173 
in several organs including intestine, esophagus, heart kidney, liver and so on by a cross-
seeding effect, deposition of ATTR was not observed. Thus, these experiments present, for 
the first time, evidence that the degree of ATTR inducibility is low relative to that of 
AApoAII. This leads us to suggest that administration of ATTR may not explain the genetic 
anticipation that occurs in FAP. 
5. Discussion and conclusion 
The amyloidogenic SAMP1, congenic R1.P1-ApoA2c and transgenic mApoA2cTg strains did 
not experience spontaneous amyloid deposition when they were reared in specific pathogen 
free (SPF) and amyloidosis-free conditions. This finding suggested that environmental 
conditions affect amyloidosis and that pre-existing amyloid fibrils make a significant 
contribution to the transmission or induction of AApoAII amyloidosis in vivo. (Higuchi et 
al., unpublished data). Moreover, cross-seeding between heterogeneous amyloid fibrils or 
fibril-like structures and amyloidogenic proteins has been reported in vitro and in vivo in 
both mouse AApoAII and AA amyloidosis (Fu et al., 2004; P. Westermark et al., 2009). Thus, 
the possibility of acceleration and induction of amyloidosis in animals and humans by 
heterogeneous amyloid fibrils in foods or the environment should be considered (Fig.6).  
 
 
Fig. 6. Transmission mechanism in systemic AApoAII and AA amyloidosis. HDL-
associated ApoA-II and SAA circulate in the blood. Spontaneous formation of the nucleus is 
slow and rare. Homologous or heterologous amyloid fibrils act as seeds and facilitate the 
formation of amyloid fibrils (self and cross-seeding). Extended amyloid fibrils were 
fragmented to make new seeds. ●: Fibril associated molecules that stabilize or modify the 
amyloid fibril structure. Amyloid fibrils are excreted from the body into feces, milk, saliva 
and muscle, and other animals may then take these into their bodies. Transmission should 
be observed at 3 levels; intra-animal, intra-organ and intra cells. 
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Recently, researchers have recognized that misfolded proteins play important roles in 
many neuro- degenerative diseases, including Alzheimer’s disease (Eisele et al., 2010), 
Parkinson’s disease (Hansen et al., 2011), Huntington’s disease (Ren et al., 2009), 
tauopathies (Clavaguera et al 2009) and so on. These disorders resemble classic prion 
diseases, as the disease can be spread by imparting the pathological structure of the 
proteins to new and normal cellular counterparts, and these seeds can recruit endogenous 
proteins (Angot et al., 2010).  Although none of these mis-folded proteins behave like 
typical infectious agents, the possible exception is systemic AApoAII and AA amyloidosis 
(Walker et al., 2006; G.T. Westermark & P. Westermark, 2010). Inter-individual infectivity 
of these two amyloidoses has been revealed experimentally and clinical outcomes are 
similar to those of the prion diseases. However, a paucity of epidemiological evidence 
argues against the role that transmission of amyloidosis may play in the human 
amyloidosis. How do the pathologic agents (amyloid fibrils) penetrate the recipient body? 
How do they spread throughout the body?  Our studies have revealed that feces, milk, 
saliva and muscle are possible transporters through nasal and gastric pathways for inter-
animal transmission. In particular, the amyloid fibrils in feces are noteworthy, since these 
fibrils showed higher fragility and transmissibility. Unstable species of infections prion 
(PrPSc) and yeast prion (Sup35) fibrils, which readily break and generate further free ends 
that can then act as seeds, have been reported to be important for transmission (Tanaka et 
al., 2006; Wille et al., 2009).    
Analysis of amyloid fibril formation of ß2m protein in test tubes revealed clearly the 
acceleration of fibril extension in the presence of pre-existing amyloid fibrils. However, 
injection of Aß2M fibrils did not induce amyloidosis in transgenic mice having a high blood 
concentration of human ß2m. Thus, transmission seems to not contribute to the development 
of systemic Aß2M amyloidosis associated with long-term dialysis.  However, the 
connections between in vitro studies performed in extreme and simplified conditions and in 
vivo observations in more complex organisms are important, and we need to improve and 
extend future experiments using model systems in order to understand the pathogenesis of 
human diseases.  
The concept of transmission via self-propagating structures of proteins or by seeding is 
unique, and it is important to understand the pathogenesis of protein mis-folding diseases. 
The animal models of systemic amyloidosis described here should prove valuable in further 
studies of the pathogenesis, genetics, therapeutics and transmission of amyloidosis. 
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